Dr. Chih-Jung Chang is currently the CDMO Unit vice president of EirGenix, Inc. His responsibilities CDMO business includes R&D, production, QC, PM and BD functions now. He got Ph. D. degree in National Taiwan University and studied on business program in UW of Unit State. Before EirGenix he works as director of TOT Oncology Business Unit at TTY Biopharm. He was creating business and drug development strategies for licensing and collaboration in global/China NCE (Specialty)/Biologics (NBE/Biosimilars) projects. With both technical knowledge and business acumen, Dr. Chang has extensive experiences building up new biologics and specialty pipelines that fit the company’s development strategy.
In addition, Dr. Chang has extensive experiences managing international networking and relationships for value-added bridge between early to late stage drug development.